TY - JOUR
T1 - Poly (ADP-Ribose) polymerase inhibitors
T2 - Recent advances and future development
AU - Scott, Clare L.
AU - Swisher, Elizabeth M.
AU - Kaufmann, Scott H.
N1 - Publisher Copyright:
© 2015 by American Society of Clinical Oncology.
PY - 2015/4/20
Y1 - 2015/4/20
N2 - Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive. However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors. We provide an update on PARP inhibitor clinical development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.
AB - Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive. However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors. We provide an update on PARP inhibitor clinical development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.
UR - http://www.scopus.com/inward/record.url?scp=84929440309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929440309&partnerID=8YFLogxK
U2 - 10.1200/JCO.2014.58.8848
DO - 10.1200/JCO.2014.58.8848
M3 - Review article
C2 - 25779564
AN - SCOPUS:84929440309
SN - 0732-183X
VL - 33
SP - 1397
EP - 1406
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 12
ER -